[Pharmacologic treatment of ulcers].
D000535:Aluminum / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D010890:Pirenzepine; D011453:Prostaglandins / Q000627:therapeutic use; D013392:Sucralfate
D000863:Antacids; D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D006635:Histamine H2 Antagonists; D009025:Morpholines; D010276:Parasympatholytics; D011453:Prostaglandins; D010890:Pirenzepine; D013392:Sucralfate; C012595:trithiozine; D000535:Aluminum; D002229:Carbenoxolone
Tratamiento farmacológico del ulcus.